Skip to main content
Top
Published in: International Journal of Hematology 1/2021

01-01-2021 | Multiple Myeloma | Images in Hematology

Amyloid cast nephropathy with systemic AL amyloidosis

Authors: Shinichi Mizuno, Hideyuki Kosukegawa

Published in: International Journal of Hematology | Issue 1/2021

Login to get access

Excerpt

A 68-year-old woman was admitted to our hospital with a high serum creatinine level of 3.4 mg/dL, anemia, and hypotension (77/44 mmHg). Serum and urinary immunoelectrophoresis detected Bence Jones-λ monoclonal protein. Bone marrow examination revealed 3–4% plasma cells, most of which were CD19-negative monoclonal plasma cells with dysplastic changes and λ-chain restriction. The level of serum κ-light chain was 41.8 mg/L and the λ-chain level was 4730 mg/L. Urinalysis showed proteinuria of 3.8 g/g creatinine, mostly non-albuminuric. Renal biopsy revealed tubulointerstitial nephritis with cast nephropathy. Direct fast scarlet staining was positive in the small arteries and the casts, but there was no evidence of glomerular deposits (Fig. 1a). Only λ-chain deposits in the casts were observed by light chain staining (Fig. 1b). Furthermore, amyloid deposits were found in the gastric mucosa and abdominal fat. The patient was diagnosed with systemic AL amyloidosis with acute kidney injury (AKI) caused by amyloid cast nephropathy. Three months after weekly bortezomib and dexamethasone therapy, her levels of serum creatinine and proteinuria markedly improved (1.5–1.7 mg/dL and 0.1–0.2 g/g creatinine, respectively). The λ-light chain level was also reduced by 98% and her blood pressure normalized. However, frailty caused by urinary tract infection and pneumonia made continuation of chemotherapy unfeasible after 3 years, and the patient died of multiple organ failure. On autopsy, there were few remaining amyloid casts.
Metadata
Title
Amyloid cast nephropathy with systemic AL amyloidosis
Authors
Shinichi Mizuno
Hideyuki Kosukegawa
Publication date
01-01-2021
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 1/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-03036-z

Other articles of this Issue 1/2021

International Journal of Hematology 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine